| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = -$25,475 ) |
| | 2022 | 2021 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R41AG063616 | Reversal of Tau Pathology with MSUT2 siRNA Conjugates | 001 | 2 | NIH | 4/22/2022 | $0 |
| | 2022 | 2021 | DTX PHARMA INC | 10655 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R41AG063616 | Reversal of Tau Pathology with MSUT2 siRNA Conjugates | 002 | 2 | NIH | 4/29/2022 | -$25,475 |
| | 2022 | 2020 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R41AG063616 | Reversal of Tau Pathology with MSUT2 siRNA Conjugates | 000 | 1 | NIH | 4/22/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $78,115 ) |
| | 2021 | 2021 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R41AG063616 | Reversal of Tau Pathology with MSUT2 siRNA Conjugates | 000 | 2 | NIH | 5/7/2021 | $99,938 |
| | 2021 | 2020 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R43NS119090 | Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A | 000 | 1 | NIH | 9/14/2021 | $0 |
| | 2021 | 2019 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R43TR002791 | Systemic Characterization of Novel Lipidated siRNA Conjugates | 000 | 1 | NIH | 2/21/2021 | $0 |
| | 2021 | 2019 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R43TR002702 | Development of Conjugated Oligonucleotide Therapeutics for Neuronal Disease | 000 | 1 | NIH | 2/21/2021 | $0 |
| | 2021 | 2019 | DTX PHARMA, INC. | 10655 SORRENTO VALLEY RD STE 100 | SAN DIEGO | CA | 92121-1628 | SAN DIEGO | USA | R43AG065066 | Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies | 000 | 1 | NIH | 5/5/2021 | -$21,823 |
|
| Issue Date FY: 2020 ( Subtotal = $600,952 ) |
| | 2020 | 2020 | DTX PHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS119090 | Development of PMP22 siRNA Conjugates for Treatment of Charcot-Marie-Tooth Disease Type 1A | 000 | 1 | NIH | 9/19/2020 | $387,925 |
| | 2020 | 2020 | DTX PHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R41AG063616 | Reversal of Tau Pathology with MSUT2 siRNA Conjugates | 000 | 1 | NIH | 8/17/2020 | $213,027 |
| | 2020 | 2019 | DTX PHARMA, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43AG065066 | Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies | 000 | 1 | NIH | 5/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $847,840 ) |
| | 2019 | 2019 | DTX PHARMA, LLC | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43TR002702 | Development of Conjugated Oligonucleotide Therapeutics for Neuronal Disease | 000 | 1 | NIH | 4/2/2019 | $301,212 |
| | 2019 | 2019 | DTX PHARMA, LLC | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43TR002791 | Systemic Characterization of Novel Lipidated siRNA Conjugates | 000 | 1 | NIH | 4/2/2019 | $321,555 |
| | 2019 | 2019 | DTX PHARMA, LLC | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43AG065066 | Generation of potent, safe and deliverable human Tau targeting siRNA for treatment of Tauopathies | 000 | 1 | NIH | 9/11/2019 | $225,073 |
|
|
